Kirk G. Nielsen - 09 Feb 2026 Form 4/A - Amendment Insider Report for SpyGlass Pharma, Inc. (SGP)

Reporting relationship: Director
Issuer ticker: SGP
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 11 Feb 2026, 17:13:35 UTC
Original report date: 10 Feb 2026
Prior SEC filing: 05 Feb 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen

Key filing fact

Kirk G. Nielsen filed Form 4/A - Amendment for SpyGlass Pharma, Inc. (SGP) on 11 Feb 2026.

Key facts

This page summarizes Kirk G. Nielsen's Form 4/A - Amendment filing for SpyGlass Pharma, Inc. (SGP).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 11 Feb 2026, 17:13.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001523522 Primary reporting owner

Nielsen Kirk G.

Relationship: Director
Address: C/O SPYGLASS PHARMA, INC. 27061 ALISO, CREEK RD., SUITE 100, ALISO VIEJO
Signature: /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,310,619
Date: 09 Feb 2026
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGP transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,690,230
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 1,690,230
Exercise price
Footnotes: F1, F2

SGP transaction Derivative

Series C-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -548,067
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 548,067
Exercise price
Footnotes: F1, F2

SGP transaction Derivative

Series C-2 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -548,067
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 548,067
Exercise price
Footnotes: F1, F2

SGP transaction Derivative

Series D Preferred Stock

Conversion of derivative security

Transaction value
Shares: -359,255
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 359,255
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.

Footnote F2

These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

SEC remarks

This amended Form 4 amends and restates Table II of the Form 4 filed by the Reporting Person on February 10, 2026 (the "Prior Form 4") and is being filed to correct the number of shares reported in Column 5 of Table II of the Prior Form 4 to reflect the Issuer's preferred stock converted on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock.